In murine breast cancer models, Huang et al. found that lower doses of anti-VEGFR2 antibody (DC101) therapy did not significantly change vessel density in tumors, but induced vascular normalization, polarized tumor-associated macrophages (TAMs) from an M2-like (immunosuppressive) to an M1-like phenotype (immunostimulatory), decreased myeloid-derived suppressor cells (MDSCs), and significantly increased tumor-infiltrating CD4+ and CD8+ T cells. Here, CD8A is linked to neoplasm.